Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polypsSanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps Share XSanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polypshttps://pharmaphorum.com/news/dupixent-on-notice-as-fda-reviews-gsks-nucala-for-nasal-polyps/
GSK eyes nasal polyps use for Nucala after trial successGlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation Share XGSK eyes nasal polyps use for Nucala after trial successhttps://pharmaphorum.com/news/gsk-eyes-nasal-polyps-use-for-nucala-after-trial-success/
Shingrix and Trelegy shield GSK from Advair falloutGlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs Share XShingrix and Trelegy shield GSK from Advair fallouthttps://pharmaphorum.com/news/gsk-advair-shingles-vaccine-trelegy/
EU clears GSK’s asthma drug Nucala in patient-friendly formatWith competition heating up in the severe asthma category, GlaxoSmithKline has a new EU approval that it hopes Share XEU clears GSK’s asthma drug Nucala in patient-friendly formathttps://pharmaphorum.com/news/eu-clears-gsks-asthma-drug-nucala-in-patient-friendly-format/